The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | The effects of maintenance therapy on real-world outcomes for patients with NDMM
Harsh Parmar, MD, Hackensack University Medical Center, Hackensack, NJ, discusses the effects of maintenance therapy (MT) on real-world outcomes for patients with newly diagnosed multiple myeloma (NDMM) post-stem-cell transplantation (SCT). Whilst MT has shown impressive results in randomized trials, these often have limited follow-up times and strict inclusion criteria, which may not reflect the real-world patient population. This study used the COTA real-world database, to compare MT with lenalidomide to no MT. There was a trend for improved overall survival (OS) and time to next therapy (TTNT) following a relapse in the no-MT arm of the study. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
